CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Wednesday reported a loss of $120.3 million in its first quarter.
The Cranbury, New Jersey-based company said it had a loss of 56 cents per share. Losses, adjusted for non-recurring costs, came to 39 cents per share.
The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share.
The pharmaceutical company posted revenue of $34 million in the period, also falling short of Street forecasts. Four analysts surveyed by Zacks expected $37.8 million.
Amicus Therapeutics expects full-year revenue in the range of $160 million to $180 million.
Amicus Therapeutics shares have risen 43% since the beginning of the year. The stock has fallen slightly more than 6% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FOLD at https://www.zacks.com/ap/FOLD